Shot chasers: big pharma’s covid-19 boost

The Intelligence from The Economist

The pandemic has caused a shift in how drug firms are viewed: their capacity for big-money innovation will give them immunity in the crisis. Widespread homeworking will have broad consequences, from commercial-property values to urban demographics. And a seemingly innocuous Hong Kong history exam is a window into the territory’s increasingly fraught politics. 

For full access to print, digital and audio editions of The Economist, subscribe here www.economist.com/radiooffer

Hosted on Acast. See acast.com/privacy for more information.

2020-05-26 20 min

Available Results

Generated results are saved to your library for reuse and search.

No generated results are available for this episode yet.

Transcript

No transcript is available for this episode yet.
Sign in to generate a transcript for review.
Sign in

Chapters

No chapters available.